Minerva Neurosciences Inc (NERV)
2.62
+0.14
(+5.65%)
USD |
NASDAQ |
May 15, 15:06
Minerva Neurosciences Cash from Operations (TTM): -20.76M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -20.76M |
December 31, 2023 | -14.78M |
September 30, 2023 | -12.90M |
June 30, 2023 | -17.63M |
March 31, 2023 | -18.95M |
December 31, 2022 | -24.65M |
September 30, 2022 | -25.37M |
June 30, 2022 | -24.46M |
March 31, 2022 | -25.19M |
December 31, 2021 | -24.60M |
September 30, 2021 | -26.93M |
June 30, 2021 | -28.17M |
March 31, 2021 | -29.84M |
December 31, 2020 | -33.82M |
September 30, 2020 | -40.84M |
June 30, 2020 | -40.49M |
March 31, 2020 | -43.03M |
December 31, 2019 | -43.43M |
September 30, 2019 | -39.05M |
June 30, 2019 | -39.51M |
March 31, 2019 | -40.61M |
Date | Value |
---|---|
December 31, 2018 | -41.94M |
September 30, 2018 | -41.05M |
June 30, 2018 | -6.176M |
March 31, 2018 | -1.794M |
December 31, 2017 | 3.093M |
September 30, 2017 | 3.077M |
June 30, 2017 | -26.47M |
March 31, 2017 | -25.68M |
December 31, 2016 | -25.69M |
September 30, 2016 | -23.36M |
June 30, 2016 | -24.43M |
March 31, 2016 | -25.41M |
December 31, 2015 | -24.27M |
September 30, 2015 | -22.68M |
June 30, 2015 | -44.12M |
March 31, 2015 | -39.63M |
December 31, 2014 | -35.96M |
September 30, 2014 | -32.15M |
June 30, 2014 | -5.376M |
March 31, 2014 | -3.221M |
December 31, 2013 | -2.160M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-43.43M
Minimum
Dec 2019
-12.90M
Maximum
Sep 2023
-28.72M
Average
-26.15M
Median
Cash from Operations (TTM) Benchmarks
Viking Therapeutics Inc | -54.87M |
Janux Therapeutics Inc | -51.50M |
ACADIA Pharmaceuticals Inc | 63.71M |
CytomX Therapeutics Inc | -91.43M |
Calidi Biotherapeutics Inc | -- |